These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 31362819)

  • 21. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013.
    Girard MP; Tam JS; Pervikov Y; Katz JM
    Vaccine; 2013 Aug; 31(37):3766-71. PubMed ID: 23810374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting.
    Edwards K; Hanquet G; Black S; Mignot E; Jankosky C; Shimabukuro T; Miller E; Nohynek H; Neels P
    Biologicals; 2019 Jul; 60():1-7. PubMed ID: 31130313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
    Wacheck V; Egorov A; Groiss F; Pfeiffer A; Fuereder T; Hoeflmayer D; Kundi M; Popow-Kraupp T; Redlberger-Fritz M; Mueller CA; Cinatl J; Michaelis M; Geiler J; Bergmann M; Romanova J; Roethl E; Morokutti A; Wolschek M; Ferko B; Seipelt J; Dick-Gudenus R; Muster T
    J Infect Dis; 2010 Feb; 201(3):354-62. PubMed ID: 20039806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
    Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
    Onishchenko GG; Zverev VV; Katlinskiĭ AV; Semchenko AV; Korovkin SA; Mel'nikov SIa; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):15-9. PubMed ID: 17882832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
    Palkonyay L; Fatima H
    Vaccine; 2016 Oct; 34(45):5414-5419. PubMed ID: 27498212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
    Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
    Front Immunol; 2018; 9():3103. PubMed ID: 30761157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards universal influenza vaccines?
    Osterhaus A; Fouchier R; Rimmelzwaan G
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2766-73. PubMed ID: 21893539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine.
    Viboud C; Gostic K; Nelson MI; Price GE; Perofsky A; Sun K; Sequeira Trovão N; Cowling BJ; Epstein SL; Spiro DJ
    PLoS Pathog; 2020 Sep; 16(9):e1008583. PubMed ID: 32970783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and Control of Seasonal Influenza with Vaccines.
    Grohskopf LA; Sokolow LZ; Broder KR; Olsen SJ; Karron RA; Jernigan DB; Bresee JS
    MMWR Recomm Rep; 2016 Aug; 65(5):1-54. PubMed ID: 27560619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
    Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
    J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live attenuated intranasal influenza vaccine.
    Esposito S; Montinaro V; Groppali E; Tenconi R; Semino M; Principi N
    Hum Vaccin Immunother; 2012 Jan; 8(1):76-80. PubMed ID: 22251995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
    J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    Carter NJ; Plosker GL
    BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.